Sign Up Today

Looking for the next hot penny stock? We can help you find it. Sign up now to start receiving our FREE alerts today!

The next explosive penny stock is out there! SIGN UP NOW!

Your e-mail is never sold or shared. Disclaimer | Privacy Policy

Planet Penny Stocks

Members receive:

- Breakout penny stock alerts
- Market movers
- In depth profiles
- Timely information

MultiCell Technologies, Inc. (MCET) surges after reports of Positive Preclinical Results in Primary Liver Cancer In Vitro Models

Posted by :: admin on May 17, 2012

Shares of MultiCell Technologies, Inc. (MCET) were up as high as 72% from Tuesday’s closing price on Wednesday after the company reported Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models.  The penny stock MCET surged with volume up from daily average of 3.57 million to 114.85 million.

About MCT-465 and MCT-485

MCT-465 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented TLR3 signaling technology.  MCT-465 and MCT 485 are in preclinical development, and are being investigated as prospective treatments for primary liver cancer and triple negative breast cancer.

Cancer stem cells are thought to play a role in a tumor’s resistance to therapy.  While significant progress has been made in developing cancer therapies that result in cytoreduction and thus tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal.  Cancer stem cells are believed to be responsible for cancer relapse by being less sensitive to conventional therapies.

MCET’s representatives will present preclinical research findings for MCT-465 and MCT-485 at CIMT (Association for Cancer Immunotherapy) 2012 in Germany, which is Europe’s largest meeting dedicated to cancer immunotherapy research and development.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. (MultiCell) is a biopharmaceutical company. MultiCell is engaged developing therapeutics and discovery tools to address unmet medical needs for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology and peripheral vessel applications. MultiCell is pursuing research and development targeting degenerative neurological diseases, including multiple sclerosis (MS) and cancer. MultiCell operates three subsidiaries, which include MCT Rhode Island Corp. (wholly owned); Xenogenics Corporation (Xenogenics) (95.3% owned, on an as-if-convertd basis), and MultiCell Immunotherapeutics, Inc. (MCTI), of which MultiCell holds approximately 67% of interests. As of November 30, 2010, the Company’s portfolio of drug candidates, which were in various stages of discovery optimization, and preclinical and clinical development included MCT-125, MCT-465, MCT-475 and MCT-485.

SCOLR Pharma (SCLR) Announces Final Closing of Private Placement

Posted by :: Planet Penny Stocks on Jul 01, 2011

SCOLR Pharma, Inc. (SCLR) announced on Thursday that it has closed the second and final tranche of its previously-announced private placement of its 8 percent Senior Secured Convertible Debentures due 2013 (the “Debentures”).  The Company raised a total of $1,190,200 in the offering.  The Company intends to use the net proceeds for working capital and other general corporate purposes.

Taglich Brothers, Inc. acted as placement agent in connection with the offering.  SCLR will pay Taglich a success fee equal to 7 percent of the gross proceeds of the sale of the Debentures.  Taglich Brothers will also receive a warrant to purchase a number of shares of common stock equal to 5% of the total number of shares into which the principal amount of the Debentures sold in the offering are convertible.  The exercise price of the warrant is $0.0625 per share.

“The completion of this offering will allow us to continue to focus on the development of our nutritional business and on our efforts to secure licensing or partnership support for our pharmaceutical products,” said SCLR’s President and CEO Stephen Turner in a June 30 press release.  “We are making good progress in placing our nutritional products on retail shelves and this capital will enable us to be even more aggressive in those efforts.”

SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented Controlled Delivery Technology (CDT) platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products.

Copyright © Planet Penny Stocks 2018. All Rights Reserved.